Target
HER-2
5 abstracts
Abstract
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).Org: Miami Neuroscience Institute,
Abstract
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.Org: Grow School for Oncology and Reproduction, European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, European Institute of Oncology - IRCCS, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Robert Debré University Hospital,
Abstract
Analysis of pathological complete response (PCR) and impact of modifiable risk factors on the premature discontinuation of pertuzumab use in early stage HER-2 breast cancer: A retrospective single-institutional study.Org: Marshall University School of Medicine, Edwards Cancer Center, Marshall University Joan C. Edwards School of Medicine,
Abstract
Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.Org: Saint Mary's and Saint Clare's Hospital, New York Medical College - Saint Michael's Medical Center, Schulich School of Medicine and Dentistry, BronxCare Health System, Dr. V.R.K. Women’s Medical College,
Abstract
Male breast cancer survival data and clinicopathological characteristics: A single-centre experience.Org: Hospital Agios Savvas, Agios Savvas Cancer Hospital, Saint Savvas Hospital, Agios Savvas Anticancer Hospital, Second Department of Medical Oncology,